A triple-drug regimen combining two immunotherapy agents with radiation before surgery appears to activate immune defenses against aggressive soft tissue sarcomas, based on early phase II data presented at the 2025 Connective Tissue Oncology Society (CTOS) annual meeting. The approach pairs the checkpoint inhibitor pembrolizumab with eftilagimod alpha, a soluble LAG-3 protein designed to stimulate antigen-presenting cells, alongside standard preoperative radiotherapy. If the immune signals hold up in longer follow-up, the strategy could shift how oncologists prepare sarcoma patients for the operating room.
What the EFTISARC-NEO Trial Tested
The phase II trial, formally registered as EFTISARC-NEO, enrolled patients with high-risk soft tissue sarcoma and treated them with pembrolizumab, eftilagimod alpha, and neoadjuvant radiotherapy before surgical resection. Immutep, the Australian immunotherapy company that develops eftilagimod alpha, sponsored the study. The primary endpoint centered on pathologic response at the time of tumor removal, specifically measuring changes such as fibrosis, hyalinization, and the percentage of viable tumor cells remaining in resected specimens.
That choice of endpoint was deliberate. An earlier observational analysis in sarcoma pathology had established that the degree of fibrosis, hyalinization, and infarction found in tumor tissue after neoadjuvant radiation correlates with improved survival. In other words, the more the tumor is replaced by scar-like tissue before the surgeon cuts, the better the patient tends to do afterward. EFTISARC-NEO adopted that pathologic yardstick as a surrogate for long-term benefit, a reasonable but still unproven shortcut that future data will need to validate.
Early Signals From CTOS 2025
An Immutep announcement distributed on November 13, 2025, described “significant pathologic response rates” and translational data pointing to enhanced immune activation within the tumor microenvironment. The oral presentation at CTOS highlighted changes in immune cell populations around and inside tumors, suggesting the triple combination did more than radiation alone typically achieves. Specifically, the company pointed to evidence of increased T-cell infiltration and shifts in the local immune balance that could, in theory, help the body recognize and attack residual cancer cells after surgery.
These are encouraging signals, but readers should weigh them carefully. The full efficacy dataset has not yet appeared in a peer-reviewed journal, and the claims rest on conference-stage results filtered through a corporate announcement. Pathologic response, while linked to survival in retrospective analyses, is not a validated surrogate endpoint for sarcoma in the way that pathologic complete response is for breast cancer. Until event-free survival or overall survival data mature, the clinical meaning of these immune changes remains an open question.
Building on the SU2C-SARC032 Foundation
EFTISARC-NEO did not emerge from thin air. Its design builds on findings from the pembrolizumab-plus-radiation trial reported in The Lancet Oncology, an open-label, randomized study that tested perioperative anti–PD-1 therapy combined with preoperative radiotherapy and surgery against radiotherapy and surgery alone in patients with stage III soft tissue sarcoma of the extremity. That study, registered as NCT03092323, provided evidence that adding immunotherapy to the standard radiation-plus-surgery sequence could improve outcomes in high-risk patients without unacceptable additional toxicity.
The randomized design and prospective follow-up distinguished SU2C-SARC032 from earlier, smaller efforts. Investigators used event-free survival as a key endpoint and monitored local control, distant metastases, and safety, helping establish that perioperative pembrolizumab could be integrated into sarcoma care pathways. A related Lancet report on neoadjuvant immunotherapy in solid tumors has reinforced the broader principle that immune checkpoint blockade given before surgery can reshape both pathologic response rates and long-term outcomes across several cancer types.
The logical next question was whether a second immune-activating agent could amplify the benefit. Eftilagimod alpha works through a different mechanism than pembrolizumab. While pembrolizumab releases the brakes on T cells by blocking the PD-1 checkpoint, eftilagimod alpha is designed to press the accelerator by engaging MHC class II molecules on antigen-presenting cells, potentially priming a broader immune response against tumor antigens released by radiation-damaged cancer cells. The EFTISARC-NEO investigators bet that combining brake-release and accelerator-press before surgery would produce a stronger immune reaction than either approach alone.
Why Pathologic Response Matters for Patients
For people diagnosed with high-risk soft tissue sarcoma, the central fear is recurrence. Even after successful surgery and radiation, a substantial fraction of patients develop metastatic disease, often in the lungs, within a few years. Standard neoadjuvant radiation shrinks tumors and improves local control, but it does relatively little to prime the immune system against distant spread. Research cataloged in related sarcoma series has shown that when preoperative treatment induces extensive fibrosis and infarction in the tumor bed, patients tend to live longer, likely because those tissue changes reflect a more thorough destruction of cancer cells before surgery.
If the triple combination genuinely amplifies that destruction and simultaneously trains immune memory cells to patrol for micrometastases, it could address both local and distant recurrence risks at once. That dual payoff is what makes the EFTISARC-NEO hypothesis compelling, even at this early stage. But compelling hypotheses have failed before in sarcoma, a family of cancers notorious for biological diversity and treatment resistance.
Gaps That Still Need Filling
Several pieces of evidence are missing from the current picture. First, the CTOS presentation and company statement have not yet been accompanied by a full manuscript. Without detailed tables showing individual patient responses, histologic subtypes, and follow-up duration, it is impossible for outside clinicians to gauge how broadly applicable the findings may be. High-grade undifferentiated pleomorphic sarcoma, myxoid liposarcoma, and synovial sarcoma, for example, may not respond in the same way to immune priming, and small imbalances in subtype enrollment can skew early pathologic data.
Second, the durability of any observed benefit remains unknown. Pathologic response is measured at a single time point, the day of surgery. Long-term outcomes such as event-free survival and overall survival will require years of follow-up. The experience from SU2C-SARC032, documented both in the trial registry and the published report, underscores how critical those time-to-event endpoints are for interpreting neoadjuvant strategies in sarcoma.
Third, safety in broader practice will need careful scrutiny. Combining two immune agents with radiation raises the possibility of overlapping toxicities, including pneumonitis, dermatitis, and autoimmune reactions that might complicate wound healing or delay surgery. While the early EFTISARC-NEO experience has not flagged prohibitive safety signals in public summaries, more granular reporting will be essential, especially for centers that do not routinely deliver complex multimodal regimens.
Finally, questions remain about how best to select patients. Translational work from neoadjuvant immunotherapy studies, including analyses summarized in recent immune profiling, suggests that baseline tumor-infiltrating lymphocytes, interferon-gamma signatures, and other biomarkers may predict who benefits most from checkpoint blockade. EFTISARC-NEO’s translational arm may eventually clarify whether such markers can guide the use of eftilagimod alpha plus pembrolizumab in sarcoma, or whether the regimen should be offered broadly to all high-risk cases.
What Comes Next
For now, EFTISARC-NEO should be viewed as a promising but still exploratory effort to deepen the impact of neoadjuvant therapy in soft tissue sarcoma. The trial’s reliance on pathologic response as a primary endpoint reflects a pragmatic attempt to generate signals of activity quickly, but the field will ultimately demand confirmation in survival curves. As more mature data emerge, clinicians and patients will want to know not only whether tumors look more damaged under the microscope, but whether that microscopic damage translates into fewer relapses, longer lives, and preserved limb function.
If those answers turn out to be positive, the triple combination of pembrolizumab, eftilagimod alpha, and radiation could become a new template for perioperative sarcoma care, potentially in combination with other systemic agents. If the answers are negative or mixed, the translational insights from EFTISARC-NEO may still help refine future trials, pointing toward better biomarkers, more rational combinations, or different timing of immunotherapy around surgery. Either way, the study illustrates how lessons from earlier efforts like SU2C-SARC032 are being extended in an effort to move the needle for a group of patients who urgently need better options.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
